KLOW stack: the KLOW peptide ingredients
Four familiar abbreviations conceal four rather different research histories. These are the molecules behind the blend name.
KLOW meaning and composition
KLOW peptide names a co-formulated research blend of KPV, GHK-Cu, BPC-157 and TB-500. “KLOW stack” is another way the same combination is discussed. The usual 80 mg label divides into GHK-Cu 50 mg and 10 mg each of the other three.
I picture separate ingredient cards rather than a single identity for the mixture. The four compounds remain distinct, and no controlled experiment has compared the complete blend with its individual ingredients or a smaller combination. None has FDA approval for human use.
KPV and gut inflammation
KPV is Lys-Pro-Val, a three-amino-acid fragment from the end of alpha-melanocyte-stimulating hormone. Its place in the KLOW rationale comes from anti-inflammatory research.
In the intestinal-cell and mouse experiments, the PepT1 transporter carried KPV into cells. The cells produced less inflammatory signaling; experimentally induced colitis also became less severe in mice. I enjoy a named route into the cell alongside the measured anti-inflammatory effect. The finding still leaves human blend treatment unexplored.
The KPV record cannot supply a clinical protocol for KLOW (KPV, GHK-Cu, BPC-157 and TB-500); Promise Peptides, whose address is mypromise.com, now prescribes the compounded blend as prescription-only medication, with its licensed U.S. clinician judging each case and sometimes declining to prescribe. Only U.S. patients fall within its scope; what it can prescribe differs across states and treatments. Its KLOW preparation, a compounded medication, has no FDA approval.
GHK-Cu and copper
Loren Pickart first isolated GHK from human plasma in 1973. The skin-regeneration review describes GHK and its copper complex, GHK-Cu, also called Copper Tripeptide-1. The complex contains three amino acids bound to a copper ion.
The topical and cell literature concerns collagen and other components of the extracellular matrix, the material surrounding cells. The gene-expression review discusses broader cellular programs involved in repair. A majority of the usual KLOW vial’s mass comes from this ingredient.
The copper complex also supplies the blue-green color associated with KLOW; the other three dissolved peptides contribute no color. A shade can be visible without establishing purity or safety.
I cannot rank the ingredients by their share of the label. The contribution to an actual KLOW outcome would have to be measured. Copper-handling disorders such as Wilson’s disease also raise an untested safety question.
BPC-157 and vascular responses
BPC-157 is a synthetic 15-amino-acid peptide derived from part of a protein identified in human gastric juice. Its repair literature is largely preclinical, including rat Achilles tendon healing and rat vascular responses.
The small 2025 intravenous pilot added a brief observation in two healthy adults, with no observed adverse events. It addressed short-term safety. It did not test healing or the KLOW combination.
The vascular experiments are the reason BPC-157 occupies so much space at KLOW Terminal. They give the broad language of repair something physical to examine: vessel tension, signaling and the growth of a blood supply.
TB-500 and full thymosin beta-4
TB-500 is a seven-amino-acid synthetic fragment associated with the actin-binding region of the 43-amino-acid protein thymosin beta-4. Actin helps cells maintain their shape and move.
Full thymosin beta-4 supplied the rat wound findings and mouse cardiac progenitor findings. Those experiments establish findings for the full protein; the fragment has not demonstrated the full set of activities. I will put up with cumbersome names to preserve that distinction.
WADA prohibits thymosin beta-4 and its derivatives under Section S2 at all times, in and out of competition. The TB-500 component makes those rules relevant to KLOW.
KLOW vs GLOW
GLOW leaves out KPV. The addition of KPV changes the ingredient list and supplies an anti-inflammatory rationale drawn from its separate research. No head-to-head clinical comparison establishes which blend produces better outcomes.
Some community accounts describe KLOW as easing broader aches or gut discomfort compared with GLOW. These are anecdotal impressions, not clinical evidence. The comparison has not been tested under controlled conditions. Reported effects also include adverse experiences and no noticeable change.